Parra, H S <br/><br/>
Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP).  [electronic resource] 

 -  Cancer  Aug 2001 
 - 650-6 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>0008-543X 
<br/><br/><label>Standard No.: </label>10.1002/1097-0142(20010801)92:3<650::aid-cncr1366>3.0.co;2-0  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Cisplatin--administration & dosage<br/>Doxorubicin--administration & dosage<br/>Female<br/>Humans<br/>Interferon alpha-2<br/>Interferon-alpha--administration & dosage<br/>Male<br/>Mesothelioma--drug therapy<br/>Middle Aged<br/>Neoplasm Staging<br/>Pleural Neoplasms--drug therapy<br/>Recombinant Proteins<br/>Survival Rate<br/>Treatment Outcome